Literature DB >> 17928404

Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Michelle L Steinhilb1, Dora Dias-Santagata, Tudor A Fulga, Daniel L Felch, Mel B Feany.   

Abstract

Tau is a microtubule binding protein implicated in a number of human neurodegenerative disorders, including Alzheimer's disease. Phosphorylation of serine-proline/threonine-proline sites, targeted by proline-directed kinases, coincides temporally with neurodegeneration in the human diseases. Recently, we demonstrated that this unique group of serines and threonines has a critical role in controlling tau toxicity in a Drosophila model of tauopathy. Here, we use a combination of genetic and biochemical approaches to examine these sites individually and to determine which of them is primarily responsible for controlling tau neurotoxicity. Despite the importance placed on individual phosphoepitopes and their contributions to disease pathogenesis, our results indicate that no single phosphorylation residue plays a dominant role in controlling tau toxicity. These findings suggest that serine-proline/threonine-proline sites cooperate to mediate neurodegeneration in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928404      PMCID: PMC2096612          DOI: 10.1091/mbc.e07-04-0327

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  46 in total

1.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

2.  Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.

Authors:  C W Wittmann; M F Wszolek; J M Shulman; P M Salvaterra; J Lewis; M Hutton; M B Feany
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

3.  Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly.

Authors:  C W Scott; R C Spreen; J L Herman; F P Chow; M D Davison; J Young; C B Caputo
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

4.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

5.  A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.

Authors:  Ya-Li Zheng; Bing-Sheng Li; Niranjana D Amin; Wayne Albers; Harish C Pant
Journal:  Eur J Biochem       Date:  2002-09

6.  Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology.

Authors:  Claude-Alain Maurage; Nicolas Sergeant; Marie-Magdeleine Ruchoux; Jean-Jacques Hauw; André Delacourte
Journal:  Acta Neuropathol       Date:  2002-09-07       Impact factor: 17.088

7.  PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila.

Authors:  Isao Nishimura; Yufeng Yang; Bingwei Lu
Journal:  Cell       Date:  2004-03-05       Impact factor: 41.582

8.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.

Authors:  Wen-Lin An; Richard F Cowburn; Lin Li; Heiko Braak; Irina Alafuzoff; Khalid Iqbal; Inge-Grundke Iqbal; Bengt Winblad; Jin-Jing Pei
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

9.  GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila.

Authors:  A Mudher; D Shepherd; T A Newman; P Mildren; J P Jukes; A Squire; A Mears; J A Drummond; S Berg; D MacKay; A A Asuni; R Bhat; S Lovestone
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

10.  Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila.

Authors:  George R Jackson; Martina Wiedau-Pazos; Tzu-Kang Sang; Naveed Wagle; Carlos A Brown; Sasan Massachi; Daniel H Geschwind
Journal:  Neuron       Date:  2002-05-16       Impact factor: 17.173

View more
  91 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

Review 3.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

4.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

5.  Lamin Dysfunction Mediates Neurodegeneration in Tauopathies.

Authors:  Bess Frost; Farah H Bardai; Mel B Feany
Journal:  Curr Biol       Date:  2015-12-24       Impact factor: 10.834

6.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

Review 7.  Recent advances in using Drosophila to model neurodegenerative diseases.

Authors:  Bingwei Lu
Journal:  Apoptosis       Date:  2009-08       Impact factor: 4.677

8.  Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts.

Authors:  Erkan Kiris; Donovan Ventimiglia; Mehmet E Sargin; Michelle R Gaylord; Alphan Altinok; Kenneth Rose; B S Manjunath; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2011-02-02       Impact factor: 5.157

9.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

Review 10.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.